Recombinant Human TFPI Protein(His Tag)

Catalog Number: PDMH100339



Note: Centrifuge before opening to ensure complete recovery of vial contents.

				ption		
	06		TO T	m	11	\mathbf{n}
v					ш	w

Species Human

Source Mammalian-derived Human TFPI proteins Asp29-Lys282, with an C-terminal His

 Mol_Mass
 27.8 kDa

 Accession
 P10646

Bio-activity Not validated for activity

Properties

Purity > 90% as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping

This product is provided as lyophilized powder which is shipped with ice packs.

Formulation


Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol

Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution of

0.5 mg/mL. Concentration is measured by UV-Vis.

Data



SDS-PAGE analysis of Human TFPI proteins, 2 µg/lane of Recombinant Human TFPI proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 42 KD

Background

For Research Use Only

Recombinant Human TFPI Protein(His Tag)

Catalog Number: PDMH100339



Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signaling activities. It is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. With its Kunitz domains, TFPI exhibits significant homology with human inter-alpha-trypson inhibitor and bovin basic pancreatic trypsin inhibitor. TFPI is the natural inhibitor of TF coagulant and signaling activities. The importance of TFPI in the regulation of blood coagulation is emphasized by how its activity is modulated in human disease. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In addition, studies have shown that TFPI exhibits antiangiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumor cell-associated TFPI are shown to significantly reduce tumor cell-induced coagulation activation and lung metastasis.